A regulatory role for CHD2 in myelopoiesis

Epigenetics. 2020 Jun-Jul;15(6-7):702-714. doi: 10.1080/15592294.2019.1710913. Epub 2020 Jan 10.

Abstract

The transcriptional program that dictates haematopoietic cell fate and differentiation requires an epigenetic regulatory and memory function, provided by a network of epigenetic factors that regulate DNA methylation, post-translational histone modifications and chromatin structure. Disturbed epigenetic regulation causes perturbations in the blood cell differentiation program that results in various types of haematopoietic disorders. Thus, accurate epigenetic regulation is essential for functional haematopoiesis. In this study, we used a CRISPR-Cas9 screening approach to identify new epigenetic regulators in myeloid differentiation. We designed a Chromatin-UMI CRISPR guide library targeting 1092 epigenetic regulators. Phorbol 12-myristate 13-acetate (PMA) treatment of the chronic myeloid leukaemia cell line K-562 was used as a megakaryocytic myeloid differentiation model. Both previously described developmental epigenetic regulators and novel factors were identified in our screen. In this study, we validated and characterized a role for the chromatin remodeller CHD2 in myeloid proliferation and megakaryocytic differentiation.

Keywords: CHD2; CRISPR-Cas9 library; epigenetics; myelopoiesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Proliferation
  • Chromatin Assembly and Disassembly
  • DNA-Binding Proteins / genetics*
  • DNA-Binding Proteins / metabolism
  • Humans
  • K562 Cells
  • Megakaryocytes / drug effects
  • Megakaryocytes / metabolism
  • Myelopoiesis*
  • Tetradecanoylphorbol Acetate / pharmacology

Substances

  • CHD2 protein, human
  • DNA-Binding Proteins
  • Tetradecanoylphorbol Acetate

Grants and funding

This work was supported by the Barncancerfonden [TJ2015-0064];Cancerfonden [CAN 2017/427];Cancerfonden [CAN2016/576];Vetenskapsrådet (SE) [4-244/2016];Radiumhemmets Forskningsfonder [171113];Vetenskapsrådet [VR2015-02312].